BioSeek | GenomeWeb

BioSeek

NEW YORK (GenomeWeb News) – DiscoveRx today said that it has acquired BioSeek, maker of the BioMAP platform of cell-based disease models for drug screening.
Financial terms of the deal were not disclosed.

NEW YORK (GenomeWeb News) – BioSeek today said that the US Environmental Protection Agency has extended the firm's contract to participate in the ToxCast screening program.

A research team led by scientists at proteomics firm Cellzome has developed a selective inhibitor to the PI3 kinase isoform PI3Kγ.

Cellzome will use the BioMap platform in its inflammatory disease drug discovery projects.

BioSeek will apply its BioMap predictive human disease models to screen Amylin's library.

The Japanese pharmaceutical developer has licensed the BioMap platform for drug toxicology research projects.

BioSeek will use its BioMap system to conduct screening for Ono Pharmaceuticals in its compound studies.

The acquisition will combine Asterand's tissue-based services for drug discovery with BioSeek's BioMap platform and human cell-based assays.

The firm will profile compounds for the second phase of the EPA initiative.

Pages

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.